RxDoctor Payments Data

Lazia van Wieringen, PA

Medical · Mount Vernon, WANPI 1871114645

Payments from drug & device makers

$549in general payments, 2019–2025

Across 29 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$222
  • Amgen$82
  • Johnson & Johnson$53
  • Novartis$38
  • AstraZeneca$36
  • Sobi, Inc$28
  • plus $89 from 5 others

What the payments were for

  • Food & beverage$549100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie12$222
Amgen4$82
Johnson & Johnson3$53
Novartis2$38
AstraZeneca2$36
Sobi, Inc1$28
Laborie Medical Technologies Corp.1$25
Mylan Institutional Inc.1$18
Sanofi1$16
Aurinia Pharma U.S., Inc.1$16
GSK1$14

How this compares

$549 in reported general payments places this provider in the 65th percentile of 457 medical providers in Washington.

See all medical providers in Washington

Medicare billing

Part B allowed, 2024
$64,026
Medicare patients
228
Services billed
1,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept52$442,661
RinvoqUpadacitinib27$186,323
Cosentyx Sensoready (2 Pens)Secukinumab25$154,806
Humira(Cf) PenAdalimumab18$124,075
EnbrelEtanercept18$122,560
Cosentyx Sensoready PenSecukinumab11$106,814
Humira(Cf)Adalimumab12$98,661
Cimzia (2 Pack)Certolizumab Pegol15$80,440
Cosentyx Unoready PenSecukinumab11$79,562
RemicadeInfliximab12$33,737
Hydroxychloroquine Sulfate178$9,526
MethotrexateMethotrexate Sodium303$7,745
Prednisone358$3,282
Pilocarpine Hcl24$1,827
Sulfasalazine59$1,411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$222$284,98439 claims
AmgenEnbrel$82$122,56018 claims
Johnson & JohnsonRemicade$53$33,73712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 457 medical providers in Washington.

Other medical in Mount Vernon

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →